Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00143234 |
The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines
Condition | Intervention | Phase |
---|---|---|
Hypertension Hyperlipidemia |
Drug: Amlodipine/atorvastatin single pill |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Clinical Utility of Amlodipine/Atorvastatin to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia |
Estimated Enrollment: | 1825 |
Study Start Date: | May 2004 |
Estimated Study Completion Date: | July 2005 |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A3841024 |
Study First Received: | August 31, 2005 |
Last Updated: | October 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00143234 |
Health Authority: | Taiwan: Department of Health |
Calcium, Dietary Metabolic Diseases Hyperlipidemias Vascular Diseases Metabolic disorder |
Atorvastatin Dyslipidemias Amlodipine Lipid Metabolism Disorders Hypertension |
Antimetabolites Vasodilator Agents Molecular Mechanisms of Pharmacological Action Antilipemic Agents Calcium Channel Blockers Enzyme Inhibitors Cardiovascular Agents |
Anticholesteremic Agents Antihypertensive Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Membrane Transport Modulators Therapeutic Uses Cardiovascular Diseases |